Iterum Therapeutics   Report issue

For profit Phase 3 Phase 4
Founded: Dublin Ireland (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2017
NCT03366207
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Iterum Therapeutics | Iterum Therapeutics, International Limited | Iterum Therapeutics, US Limited

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 4)

Infections (Phase 4)

Intraabdominal Infections (Phase 3)

Urinary Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 9